Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Debt to Equity (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Debt to Equity over the past 15 years, most recently at $4.34 for Q2 2025.

  • For Q2 2025, Debt to Equity fell 51.64% year-over-year to $4.34; the TTM value through May 2025 reached $4.34, down 51.64%, while the annual FY2025 figure was $4.34, 51.64% down from the prior year.
  • Debt to Equity for Q2 2025 was $4.34 at Lifecore Biomedical, Inc. \De\, down from $51.89 in the prior quarter.
  • Over five years, Debt to Equity peaked at $51.89 in Q1 2025 and troughed at -$26.99 in Q3 2024.
  • A 5-year average of $2.13 and a median of $0.94 in 2021 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: plummeted 1894.05% in 2023 and later surged 1101.82% in 2024.
  • Year by year, Debt to Equity stood at $1.07 in 2021, then skyrocketed by 30.08% to $1.39 in 2022, then surged by 793.06% to $12.42 in 2023, then crashed by 95.17% to $0.6 in 2024, then surged by 623.4% to $4.34 in 2025.
  • Business Quant data shows Debt to Equity for LFCR at $4.34 in Q2 2025, $51.89 in Q1 2025, and $0.6 in Q4 2024.